Literature DB >> 29396303

The Comeback of Scarlet Fever.

Samson S Y Wong1, Kwok-Yung Yuen2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29396303      PMCID: PMC5835575          DOI: 10.1016/j.ebiom.2018.01.030

Source DB:  PubMed          Journal:  EBioMedicine        ISSN: 2352-3964            Impact factor:   8.143


× No keyword cloud information.
Streptococcus pyogenes (group A Streptococcus, GAS) is arguably the most virulent of all clinically important streptococci with a propensity to cause severe invasive diseases, toxic shock syndrome, and immunopathological damages such as acute rheumatic fever. Since the 1980s, severe GAS infections such as necrotizing fasciitis and toxic shock syndrome have been increasingly recognized (Stevens and Bryant, 2016). Scarlet fever, a toxin-mediated disease, occurred in epidemics in the nineteenth century but was relatively uncommon in the second half of the twentieth century in most developed countries. However, there has been a re-emergence of scarlet fever in the past decade in some countries such as the United Kingdom (since 2014), Hong Kong (since 2011), and mainland China (Lamagni et al., 2017, Tse et al., 2012, You et al., 2018). Historically, epidemics of scarlet fever often occurred every five to six years, possibly due to the accumulation of type-specific herd immunity among the susceptible population in the community, but also affected by various environmental and meteorological factors (Wong and Yuen, 2012). The appearance of GAS epidemics has sometimes been attributed to the introduction of hitherto uncommon emm types or acquisition of new mobile genetic elements which may carry virulence determinants, although these have not been consistently demonstrated in all outbreaks. Different emm types predominate in different parts of the world. For example, the increase in scarlet fever incidence in England since 2014 was caused by multiple lineages of GAS, especially emm3, emm4, and emm12 types, while the acapsular emm89 has emerged as an important cause of invasive GAS diseases (Chalker et al., 2017). In the UK outbreak of scarlet fever in 2014, no single lineage of GAS or virulence gene predominated in all the strains (Chalker et al., 2017). In contrast, the 2011 epidemics of scarlet fever in Hong Kong and mainland China were predominantly caused by emm12 strains (Tse et al., 2012, You et al., 2018). Similarly, the commonest strains found in scarlet fever cases also belonged to emm12 type in northern Taiwan in 2010–2011 (Wu et al., 2014). However, even in scarlet fever epidemics where a particular emm type predominated, genomic studies showed that the strains often belonged to multiple phylogenetic lineages rather than a single clone (Tse et al., 2012, You et al., 2018). The emm12 type is not new to the Far East region. In China, emm12 was already the commonest emm type found in S. pyogenes isolates between 2005 and 2008. (Liang et al., 2012) The 2011 scarlet fever outbreak in Hong Kong was notable in that most of the outbreak emm12 strains were associated with new genomic insertions containing tetracycline and macrolide resistance genes, and the presence of novel prophages ΦHKU.ssa and ΦHKU.vir, which carried genes for superantigens and DNase (ssa, speC, spd1) (Tse et al., 2012). The ΦHKU.vir and ΦHKU.ssa prophages were also present in half of the contemporary Chinese scarlet fever-associated emm12 strains (You et al., 2018). In addition to the possible roles of these virulence factors in pathogenesis, the presence of macrolide resistance may impart survival advantages to these strains in areas where antibiotic consumption is high, especially where macrolides are commonly prescribed for respiratory tract infections in the primary care setting. Although the 2014 UK scarlet fever outbreak was caused by multiple emm types and lineages (but especially emm3, 4, and 12), a ΦHKU.ssa-like prophage was found in 68.3% of the emm12 isolates but not in other emm types (except for one [3.5%] emm28 isolate) (Chalker et al., 2017). The problem of clindamycin resistance has been a clinically pertinent issue for many years. Historically, clindamycin plus penicillin is the recommended treatment of severe GAS infections by reducing toxin and superantigen production (Wong and Yuen, 2012). However, the use of clindamycin is potentially detrimental in the presence of clindamycin resistance because it can paradoxically increase the production of exotoxins. In the recent scarlet fever outbreaks in Hong Kong and mainland China, clindamycin resistance was present in 85.6% and 97% of the isolates respectively (Luk et al., 2012, You et al., 2013). This high prevalence of macrolide and clindamycin resistance may necessitate the use of alternative adjunctive therapy such as linezolid in the treatment of severe GAS infections (Wong and Yuen, 2012). The use of whole genome sequencing has enhanced our understanding of the molecular epidemiology of S. pyogenes infections. It allows for detailed analysis of the emm types of strains, phylogenetic analysis, antibiotic resistance genes characterization, and discovery of novel genetic elements. The approach has been used in the study of invasive GAS infections and scarlet fever outbreaks in different countries (Chalker et al., 2017, Tse et al., 2012, You et al., 2018). The wider availability of whole genome sequencing will allow a better understanding of the epidemiology and pathogenesis of infections due to S. pyogenes.

Disclosure

The authors declared no conflicts of interest.
  9 in total

1.  Epidemiological and molecular characteristics of clinical isolates of Streptococcus pyogenes collected between 2005 and 2008 from Chinese children.

Authors:  Yunmei Liang; Xiaorong Liu; Hesheng Chang; Lili Ji; Guoying Huang; Zhou Fu; Yuejie Zheng; Libo Wang; Chengrong Li; Ying Shen; Sangjie Yu; Kaihu Yao; Lin Ma; Xuzhuang Shen; Yonghong Yang
Journal:  J Med Microbiol       Date:  2012-03-22       Impact factor: 2.472

2.  Molecular epidemiological characteristics of Streptococcus pyogenes strains involved in an outbreak of scarlet fever in China, 2011.

Authors:  Yuan Hai You; Yan Yan Song; Xiao Mei Yan; Hai Bin Wang; Meng Han Zhang; Xiao Xia Tao; Lei Lei Li; Yu Xin Zhang; Xi Hong Jiang; Bing Hua Zhang; Hao Zhou; Di Xiao; Lian Mei Jin; Zi Jian Feng; Feng Ji Luo; Jian Zhong Zhang
Journal:  Biomed Environ Sci       Date:  2013-11       Impact factor: 3.118

3.  Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study.

Authors:  Theresa Lamagni; Rebecca Guy; Meera Chand; Katherine L Henderson; Victoria Chalker; James Lewis; Vanessa Saliba; Alex J Elliot; Gillian E Smith; Stephen Rushton; Elizabeth A Sheridan; Mary Ramsay; Alan P Johnson
Journal:  Lancet Infect Dis       Date:  2017-11-27       Impact factor: 25.071

4.  Molecular characterization of the 2011 Hong Kong scarlet fever outbreak.

Authors:  Herman Tse; Jessie Y J Bao; Mark R Davies; Peter Maamary; Hoi-Wah Tsoi; Amy H Y Tong; Tom C C Ho; Chi-Ho Lin; Christine M Gillen; Timothy C Barnett; Jonathan H K Chen; Mianne Lee; Wing-Cheong Yam; Chi-Kin Wong; Cheryl-Lynn Y Ong; Yee-Wai Chan; Cheng-Wei Wu; Tony Ng; Wilina W L Lim; Thomas H F Tsang; Cindy W S Tse; Gordon Dougan; Mark J Walker; Si Lok; Kwok-Yung Yuen
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

5.  Molecular characterization of Group A streptococcal isolates causing scarlet fever and pharyngitis among young children: a retrospective study from a northern Taiwan medical center.

Authors:  Po-Chuang Wu; Wen-Tsung Lo; Shyi-Jou Chen; Chih-Chien Wang
Journal:  J Microbiol Immunol Infect       Date:  2013-04-30       Impact factor: 4.399

Review 6.  Streptococcus pyogenes and re-emergence of scarlet fever as a public health problem.

Authors:  Samson Sy Wong; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2012-07-11       Impact factor: 7.163

7.  Scarlet fever epidemic, Hong Kong, 2011.

Authors:  Emma Y Y Luk; Janice Y C Lo; Amy Z L Li; Michael C K Lau; Terence K M Cheung; Alice Y M Wong; Monica M H Wong; Christine W Wong; Shuk-kwan Chuang; Thomas Tsang
Journal:  Emerg Infect Dis       Date:  2012-10       Impact factor: 6.883

8.  Genome analysis following a national increase in Scarlet Fever in England 2014.

Authors:  Victoria Chalker; Aleksey Jironkin; Juliana Coelho; Ali Al-Shahib; Steve Platt; Georgia Kapatai; Roger Daniel; Chenchal Dhami; Marisa Laranjeira; Timothy Chambers; Rebecca Guy; Theresa Lamagni; Timothy Harrison; Meera Chand; Alan P Johnson; Anthony Underwood
Journal:  BMC Genomics       Date:  2017-03-10       Impact factor: 3.969

9.  Scarlet Fever Epidemic in China Caused by Streptococcus pyogenes Serotype M12: Epidemiologic and Molecular Analysis.

Authors:  Yuanhai You; Mark R Davies; Melinda Protani; Liam McIntyre; Mark J Walker; Jianzhong Zhang
Journal:  EBioMedicine       Date:  2018-01-11       Impact factor: 8.143

  9 in total
  2 in total

1.  Streptococcus pyogenes strains associated with invasive and non-invasive infections present possible links with emm types and superantigens.

Authors:  Rao Muhammad Abid Khan; Sana Anwar; Zaid Ahmed Pirzada
Journal:  Iran J Basic Med Sci       Date:  2020-01       Impact factor: 2.699

2.  Seasonality and trend prediction of scarlet fever incidence in mainland China from 2004 to 2018 using a hybrid SARIMA-NARX model.

Authors:  Yongbin Wang; Chunjie Xu; Zhende Wang; Juxiang Yuan
Journal:  PeerJ       Date:  2019-01-17       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.